[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f1Fhqug3Mfy0BxLWwQU2-Q5Rqzjw89FA6r0sqa0gC5Yc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":64,"rows":71},"Montreal Heart Institute",[4],100,false,22,12,88974,14,69,[14,16,19,22,24,27,29,31],{"name":15,"count":9},"Heart Failure",{"name":17,"count":18},"Coronary Artery Disease",9,{"name":20,"count":21},"Right Heart Failure",5,{"name":23,"count":21},"Atrial Fibrillation",{"name":25,"count":26},"Myocardial Infarction",4,{"name":28,"count":26},"Coronary Heart Disease",{"name":30,"count":26},"Right Ventricular Dysfunction",{"name":32,"count":26},"Congestive Heart Failure",[34,39,44,49,54,59],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05105919","Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes","2024-04-01","Aspirin 80 mg EC Tab",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT05450328","Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation","2026-11-01","Combined Epoprostenol Sodium & Milrinone",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT07524335","Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial","2027-05-01","Prescription of Aspirin",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT05702463","Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II","2027-06-01","Aspirin 81Mg Ec Tab twice daily for 7 days",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT05633810","COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes","2027-12","Aspirin",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT07257198","Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone","2030-01-01","Ticagrelor + placebo",[65,66,67,68,69,70],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[72,157,180,204,222,240,258,282,300,322,340,367,385,403,425,449,473,500,518,545,563,588,612,637,662,687,710,734,758,784,826,852,877,904,929,955],{"intervention":73,"totalTrials":74,"cells":75},"Colchicine",6,{"EARLY_PHASE1":76,"PHASE1":79,"PHASE2":81,"PHASE3":105,"PHASE4":153,"NA":155},{"trials":77,"activeCount":78},[],0,{"trials":80,"activeCount":78},[],{"trials":82,"activeCount":78},[83,95],{"nctId":84,"briefTitle":85,"status":86,"phases":87,"primaryCompletion":88,"completion":89,"start":90,"enrollment":91,"conditions":92,"interventions":94},"NCT02162303","Colchicine in Vascular Inflammation Assessed With PET Imaging","COMPLETED",[67],"2015-07","2016-01","2014-05",106,[93],"Atherosclerotic Vascular Disease",[73],{"nctId":96,"briefTitle":97,"status":98,"phases":99,"primaryCompletion":100,"completion":100,"start":101,"enrollment":11,"conditions":102,"interventions":104},"NCT04857931","Colchicine in HFpEF","TERMINATED",[67],"2023-03-07","2022-06-17",[15,103,73],"Inflammation",[73],{"trials":106,"activeCount":152,"soonestReadout":57},[107,117,130,141],{"nctId":108,"briefTitle":109,"status":98,"phases":110,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"NCT04322682","Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)",[68],"2021-01-21","2020-03-23",4506,[115],"Corona Virus Infection",[73],{"nctId":118,"briefTitle":119,"status":120,"phases":121,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":129},"NCT06217120","Reversing Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction","UNKNOWN",[67,68],"2025-10-01","2026-03-01","2024-03-01",60,[127,128],"Heart Failure With Preserved Ejection Fraction","Microvascular Coronary Artery Disease",[73],{"nctId":131,"briefTitle":132,"status":86,"phases":133,"primaryCompletion":134,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":138},"NCT02551094","Colchicine Cardiovascular Outcomes Trial (COLCOT)",[68],"2019-07-17","2015-12-04",4745,[17,25],[139,140],"colchicine","colchicine placebo",{"nctId":55,"briefTitle":56,"status":142,"phases":143,"primaryCompletion":57,"completion":57,"start":144,"enrollment":145,"conditions":146,"interventions":149},"RECRUITING",[68],"2022-12-21",10000,[147,148],"Diabete Type 2","Cardiovascular Diseases",[58,150,73,151],"Aspirin Placebo","Colchicine Placebo",1,{"trials":154,"activeCount":78},[],{"trials":156,"activeCount":78},[],{"intervention":140,"totalTrials":158,"cells":159},2,{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":166,"PHASE4":176,"NA":178},{"trials":161,"activeCount":78},[],{"trials":163,"activeCount":78},[],{"trials":165,"activeCount":78},[],{"trials":167,"activeCount":152,"soonestReadout":57},[168,172],{"nctId":131,"briefTitle":132,"status":86,"phases":169,"primaryCompletion":134,"completion":134,"start":135,"enrollment":136,"conditions":170,"interventions":171},[68],[17,25],[139,140],{"nctId":55,"briefTitle":56,"status":142,"phases":173,"primaryCompletion":57,"completion":57,"start":144,"enrollment":145,"conditions":174,"interventions":175},[68],[147,148],[58,150,73,151],{"trials":177,"activeCount":78},[],{"trials":179,"activeCount":78},[],{"intervention":63,"totalTrials":152,"cells":181},{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":200,"NA":202},{"trials":183,"activeCount":78},[],{"trials":185,"activeCount":78},[],{"trials":187,"activeCount":78},[],{"trials":189,"activeCount":152,"soonestReadout":62},[190],{"nctId":60,"briefTitle":61,"status":142,"phases":191,"primaryCompletion":62,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":198},[68],"2031-01-01","2026-03-03",2570,[196,197,25],"NSTEMI - Non-ST Segment Elevation MI","STEMI (ST Elevation MI)",[63,199],"Ticagrelor + aspirin",{"trials":201,"activeCount":78},[],{"trials":203,"activeCount":78},[],{"intervention":199,"totalTrials":152,"cells":205},{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":212,"PHASE4":218,"NA":220},{"trials":207,"activeCount":78},[],{"trials":209,"activeCount":78},[],{"trials":211,"activeCount":78},[],{"trials":213,"activeCount":152,"soonestReadout":62},[214],{"nctId":60,"briefTitle":61,"status":142,"phases":215,"primaryCompletion":62,"completion":192,"start":193,"enrollment":194,"conditions":216,"interventions":217},[68],[196,197,25],[63,199],{"trials":219,"activeCount":78},[],{"trials":221,"activeCount":78},[],{"intervention":58,"totalTrials":152,"cells":223},{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":230,"PHASE4":236,"NA":238},{"trials":225,"activeCount":78},[],{"trials":227,"activeCount":78},[],{"trials":229,"activeCount":78},[],{"trials":231,"activeCount":152,"soonestReadout":57},[232],{"nctId":55,"briefTitle":56,"status":142,"phases":233,"primaryCompletion":57,"completion":57,"start":144,"enrollment":145,"conditions":234,"interventions":235},[68],[147,148],[58,150,73,151],{"trials":237,"activeCount":78},[],{"trials":239,"activeCount":78},[],{"intervention":150,"totalTrials":152,"cells":241},{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":248,"PHASE4":254,"NA":256},{"trials":243,"activeCount":78},[],{"trials":245,"activeCount":78},[],{"trials":247,"activeCount":78},[],{"trials":249,"activeCount":152,"soonestReadout":57},[250],{"nctId":55,"briefTitle":56,"status":142,"phases":251,"primaryCompletion":57,"completion":57,"start":144,"enrollment":145,"conditions":252,"interventions":253},[68],[147,148],[58,150,73,151],{"trials":255,"activeCount":78},[],{"trials":257,"activeCount":78},[],{"intervention":48,"totalTrials":152,"cells":259},{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":264,"PHASE3":266,"PHASE4":278,"NA":280},{"trials":261,"activeCount":78},[],{"trials":263,"activeCount":78},[],{"trials":265,"activeCount":78},[],{"trials":267,"activeCount":152,"soonestReadout":47},[268],{"nctId":45,"briefTitle":46,"status":269,"phases":270,"primaryCompletion":47,"completion":271,"start":272,"enrollment":273,"conditions":274,"interventions":276},"NOT_YET_RECRUITING",[68],"2028-05-01","2026-05-01",48,[17,275],"Subclinical Atherosclerotic Cardiovascular Disease",[48,277],"No prescription",{"trials":279,"activeCount":78},[],{"trials":281,"activeCount":78},[],{"intervention":277,"totalTrials":152,"cells":283},{"EARLY_PHASE1":284,"PHASE1":286,"PHASE2":288,"PHASE3":290,"PHASE4":296,"NA":298},{"trials":285,"activeCount":78},[],{"trials":287,"activeCount":78},[],{"trials":289,"activeCount":78},[],{"trials":291,"activeCount":152,"soonestReadout":47},[292],{"nctId":45,"briefTitle":46,"status":269,"phases":293,"primaryCompletion":47,"completion":271,"start":272,"enrollment":273,"conditions":294,"interventions":295},[68],[17,275],[48,277],{"trials":297,"activeCount":78},[],{"trials":299,"activeCount":78},[],{"intervention":43,"totalTrials":152,"cells":301},{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":316,"PHASE4":318,"NA":320},{"trials":303,"activeCount":78},[],{"trials":305,"activeCount":78},[],{"trials":307,"activeCount":152,"soonestReadout":42},[308],{"nctId":40,"briefTitle":41,"status":269,"phases":309,"primaryCompletion":42,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":314},[67],"2027-01-01","2025-11-01",141,[20,30],[43,315],"Normal saline",{"trials":317,"activeCount":78},[],{"trials":319,"activeCount":78},[],{"trials":321,"activeCount":78},[],{"intervention":315,"totalTrials":152,"cells":323},{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":334,"PHASE4":336,"NA":338},{"trials":325,"activeCount":78},[],{"trials":327,"activeCount":78},[],{"trials":329,"activeCount":152,"soonestReadout":42},[330],{"nctId":40,"briefTitle":41,"status":269,"phases":331,"primaryCompletion":42,"completion":310,"start":311,"enrollment":312,"conditions":332,"interventions":333},[67],[20,30],[43,315],{"trials":335,"activeCount":78},[],{"trials":337,"activeCount":78},[],{"trials":339,"activeCount":78},[],{"intervention":53,"totalTrials":152,"cells":341},{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":359,"PHASE3":361,"PHASE4":363,"NA":365},{"trials":343,"activeCount":78},[],{"trials":345,"activeCount":152,"soonestReadout":52},[346],{"nctId":50,"briefTitle":51,"status":142,"phases":347,"primaryCompletion":52,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":356},[66],"2027-07-01","2023-06-13",30,[352,353,58,354,355],"Platelet Aggregation","Type 2 Diabetes","Diabetes Mellitus, Type 2","Platelet Aggregation Inhibitors",[53,357,358],"Aspirin 40Mg Chew Tab twice daily for 7 days","Aspirin 162 mg EC Tab once daily for 7 days",{"trials":360,"activeCount":78},[],{"trials":362,"activeCount":78},[],{"trials":364,"activeCount":78},[],{"trials":366,"activeCount":78},[],{"intervention":357,"totalTrials":152,"cells":368},{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":377,"PHASE3":379,"PHASE4":381,"NA":383},{"trials":370,"activeCount":78},[],{"trials":372,"activeCount":152,"soonestReadout":52},[373],{"nctId":50,"briefTitle":51,"status":142,"phases":374,"primaryCompletion":52,"completion":348,"start":349,"enrollment":350,"conditions":375,"interventions":376},[66],[352,353,58,354,355],[53,357,358],{"trials":378,"activeCount":78},[],{"trials":380,"activeCount":78},[],{"trials":382,"activeCount":78},[],{"trials":384,"activeCount":78},[],{"intervention":358,"totalTrials":152,"cells":386},{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":395,"PHASE3":397,"PHASE4":399,"NA":401},{"trials":388,"activeCount":78},[],{"trials":390,"activeCount":152,"soonestReadout":52},[391],{"nctId":50,"briefTitle":51,"status":142,"phases":392,"primaryCompletion":52,"completion":348,"start":349,"enrollment":350,"conditions":393,"interventions":394},[66],[352,353,58,354,355],[53,357,358],{"trials":396,"activeCount":78},[],{"trials":398,"activeCount":78},[],{"trials":400,"activeCount":78},[],{"trials":402,"activeCount":78},[],{"intervention":38,"totalTrials":152,"cells":404},{"EARLY_PHASE1":405,"PHASE1":415,"PHASE2":417,"PHASE3":419,"PHASE4":421,"NA":423},{"trials":406,"activeCount":152,"soonestReadout":37},[407],{"nctId":35,"briefTitle":36,"status":408,"phases":409,"primaryCompletion":37,"completion":410,"start":411,"enrollment":412,"conditions":413,"interventions":414},"ACTIVE_NOT_RECRUITING",[65],"2025-12-01","2021-08-26",50,[354],[38],{"trials":416,"activeCount":78},[],{"trials":418,"activeCount":78},[],{"trials":420,"activeCount":78},[],{"trials":422,"activeCount":78},[],{"trials":424,"activeCount":78},[],{"intervention":426,"totalTrials":152,"cells":427},"Candesartan up to 32 mg daily",{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":432,"PHASE3":434,"PHASE4":436,"NA":447},{"trials":429,"activeCount":78},[],{"trials":431,"activeCount":78},[],{"trials":433,"activeCount":78},[],{"trials":435,"activeCount":78},[],{"trials":437,"activeCount":78},[438],{"nctId":439,"briefTitle":440,"status":86,"phases":441,"primaryCompletion":442,"completion":442,"start":443,"enrollment":444,"conditions":445,"interventions":446},"NCT00400582","A Pharmacogenomic Study of Candesartan in Heart Failure",[69],"2010-04","2006-11",300,[15],[426],{"trials":448,"activeCount":78},[],{"intervention":450,"totalTrials":152,"cells":451},"Quinapril",{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":458,"PHASE4":460,"NA":471},{"trials":453,"activeCount":78},[],{"trials":455,"activeCount":78},[],{"trials":457,"activeCount":78},[],{"trials":459,"activeCount":78},[],{"trials":461,"activeCount":78},[462],{"nctId":463,"briefTitle":464,"status":86,"phases":465,"completion":466,"start":467,"conditions":468,"interventions":470},"NCT00269243","Management With Accupril Post Bypass Graft",[69],"2005-05","1999-11",[469],"CABG",[450],{"trials":472,"activeCount":78},[],{"intervention":474,"totalTrials":152,"cells":475},"Quinapril 40 mg",{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":498},{"trials":477,"activeCount":78},[],{"trials":479,"activeCount":78},[],{"trials":481,"activeCount":78},[],{"trials":483,"activeCount":78},[],{"trials":485,"activeCount":78},[486],{"nctId":487,"briefTitle":488,"status":98,"phases":489,"primaryCompletion":490,"completion":491,"start":492,"enrollment":493,"conditions":494,"interventions":496},"NCT00313547","High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine in the Treatment of High-Risk Hypertensive Patients",[69],"2007-04","2008-03","2006-04",40,[495],"Hypertension",[474,497],"Quinapril 10 mg and amlodipine 5 mg",{"trials":499,"activeCount":78},[],{"intervention":497,"totalTrials":152,"cells":501},{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":508,"PHASE4":510,"NA":516},{"trials":503,"activeCount":78},[],{"trials":505,"activeCount":78},[],{"trials":507,"activeCount":78},[],{"trials":509,"activeCount":78},[],{"trials":511,"activeCount":78},[512],{"nctId":487,"briefTitle":488,"status":98,"phases":513,"primaryCompletion":490,"completion":491,"start":492,"enrollment":493,"conditions":514,"interventions":515},[69],[495],[474,497],{"trials":517,"activeCount":78},[],{"intervention":519,"totalTrials":152,"cells":520},"Eplerenone",{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":527,"PHASE4":541,"NA":543},{"trials":522,"activeCount":78},[],{"trials":524,"activeCount":78},[],{"trials":526,"activeCount":78},[],{"trials":528,"activeCount":78},[529],{"nctId":530,"briefTitle":531,"status":86,"phases":532,"primaryCompletion":533,"completion":534,"start":535,"enrollment":536,"conditions":537,"interventions":539},"NCT01586442","Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes",[68],"2015-03","2018-07-29","2012-03",62,[15,353,538],"Glucose Intolerance",[519,540],"Spironolactone",{"trials":542,"activeCount":78},[],{"trials":544,"activeCount":78},[],{"intervention":540,"totalTrials":152,"cells":546},{"EARLY_PHASE1":547,"PHASE1":549,"PHASE2":551,"PHASE3":553,"PHASE4":559,"NA":561},{"trials":548,"activeCount":78},[],{"trials":550,"activeCount":78},[],{"trials":552,"activeCount":78},[],{"trials":554,"activeCount":78},[555],{"nctId":530,"briefTitle":531,"status":86,"phases":556,"primaryCompletion":533,"completion":534,"start":535,"enrollment":536,"conditions":557,"interventions":558},[68],[15,353,538],[519,540],{"trials":560,"activeCount":78},[],{"trials":562,"activeCount":78},[],{"intervention":564,"totalTrials":152,"cells":565},"Perindopril",{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":570,"PHASE3":572,"PHASE4":584,"NA":586},{"trials":567,"activeCount":78},[],{"trials":569,"activeCount":78},[],{"trials":571,"activeCount":78},[],{"trials":573,"activeCount":78},[574],{"nctId":575,"briefTitle":576,"status":86,"phases":577,"primaryCompletion":578,"completion":578,"start":579,"enrollment":580,"conditions":581,"interventions":583},"NCT00461903","Efficacy of Perindopril to Prevent Recurrence of Atrial Fibrillation in Patients With Essential Hypertension",[68],"2015-09","2007-12",316,[582,23],"Essential Hypertension",[564],{"trials":585,"activeCount":78},[],{"trials":587,"activeCount":78},[],{"intervention":589,"totalTrials":152,"cells":590},"Rivaroxaban",{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":595,"PHASE3":597,"PHASE4":608,"NA":610},{"trials":592,"activeCount":78},[],{"trials":594,"activeCount":78},[],{"trials":596,"activeCount":78},[],{"trials":598,"activeCount":78},[599],{"nctId":600,"briefTitle":601,"status":98,"phases":602,"primaryCompletion":603,"completion":603,"start":533,"enrollment":604,"conditions":605,"interventions":607},"NCT02387229","Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF",[68],"2024-05-18",1238,[606],"ATRIAL FIBRILLATION",[589],{"trials":609,"activeCount":78},[],{"trials":611,"activeCount":78},[],{"intervention":613,"totalTrials":152,"cells":614},"Bromocriptine",{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":621,"PHASE4":633,"NA":635},{"trials":616,"activeCount":78},[],{"trials":618,"activeCount":78},[],{"trials":620,"activeCount":78},[],{"trials":622,"activeCount":78},[623],{"nctId":624,"briefTitle":625,"status":626,"phases":627,"primaryCompletion":628,"completion":628,"start":629,"enrollment":78,"conditions":630,"interventions":632},"NCT02590601","Bromocriptine in the Treatment of Peripartum Cardiomyopathy","WITHDRAWN",[68],"2023-01-01","2017-01-01",[631],"Peripartum Cardiomyopathy",[613],{"trials":634,"activeCount":78},[],{"trials":636,"activeCount":78},[],{"intervention":638,"totalTrials":152,"cells":639},"OMEGA-3",{"EARLY_PHASE1":640,"PHASE1":642,"PHASE2":644,"PHASE3":646,"PHASE4":658,"NA":660},{"trials":641,"activeCount":78},[],{"trials":643,"activeCount":78},[],{"trials":645,"activeCount":78},[],{"trials":647,"activeCount":78},[648],{"nctId":649,"briefTitle":650,"status":86,"phases":651,"primaryCompletion":652,"completion":653,"start":654,"enrollment":655,"conditions":656,"interventions":657},"NCT01235130","Multi_center Study to Evaluate the Effect of N-3 Fatty Acids (OMEGA-3) on Arrhythmia Recurrence in Atrial Fibrillation",[68],"2012-12","2013-05","2009-03",337,[23],[638],{"trials":659,"activeCount":78},[],{"trials":661,"activeCount":78},[],{"intervention":663,"totalTrials":152,"cells":664},"Inhaled milrinone 5 mg",{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":681,"PHASE4":683,"NA":685},{"trials":666,"activeCount":78},[],{"trials":668,"activeCount":78},[],{"trials":670,"activeCount":78},[671],{"nctId":672,"briefTitle":673,"status":86,"phases":674,"primaryCompletion":675,"completion":676,"start":677,"enrollment":493,"conditions":678,"interventions":680},"NCT01725776","Inhaled Milrinone in Cardiac Surgery",[67],"2012-02","2012-06","2006-12",[679],"Pulmonary Hypertension",[663],{"trials":682,"activeCount":78},[],{"trials":684,"activeCount":78},[],{"trials":686,"activeCount":78},[],{"intervention":688,"totalTrials":152,"cells":689},"PulmoBind",{"EARLY_PHASE1":690,"PHASE1":692,"PHASE2":694,"PHASE3":704,"PHASE4":706,"NA":708},{"trials":691,"activeCount":78},[],{"trials":693,"activeCount":78},[],{"trials":695,"activeCount":78},[696],{"nctId":697,"briefTitle":698,"status":86,"phases":699,"primaryCompletion":578,"completion":578,"start":700,"enrollment":701,"conditions":702,"interventions":703},"NCT02216279","Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension",[67],"2014-09",45,[679],[688],{"trials":705,"activeCount":78},[],{"trials":707,"activeCount":78},[],{"trials":709,"activeCount":78},[],{"intervention":711,"totalTrials":152,"cells":712},"Avenanthramide",{"EARLY_PHASE1":713,"PHASE1":715,"PHASE2":717,"PHASE3":728,"PHASE4":730,"NA":732},{"trials":714,"activeCount":78},[],{"trials":716,"activeCount":78},[],{"trials":718,"activeCount":78},[719],{"nctId":720,"briefTitle":721,"status":86,"phases":722,"primaryCompletion":723,"completion":723,"start":724,"enrollment":725,"conditions":726,"interventions":727},"NCT06101784","Single and Multiple Ascending Oral Doses of Avenanthramide",[66,67],"2025-06-16","2023-12-09",92,[103],[711],{"trials":729,"activeCount":78},[],{"trials":731,"activeCount":78},[],{"trials":733,"activeCount":78},[],{"intervention":735,"totalTrials":152,"cells":736},"Quercetin",{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":752,"PHASE4":754,"NA":756},{"trials":738,"activeCount":78},[],{"trials":740,"activeCount":78},[],{"trials":742,"activeCount":78},[743],{"nctId":744,"briefTitle":745,"status":86,"phases":746,"primaryCompletion":747,"completion":748,"start":749,"enrollment":6,"conditions":750,"interventions":751},"NCT04907253","Quercetin in Coronary Artery By-pass Surgery",[67],"2023-12-01","2025-05-16","2021-06-04",[17],[735],{"trials":753,"activeCount":78},[],{"trials":755,"activeCount":78},[],{"trials":757,"activeCount":78},[],{"intervention":759,"totalTrials":152,"cells":760},"CP105F",{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":778,"PHASE4":780,"NA":782},{"trials":762,"activeCount":78},[],{"trials":764,"activeCount":78},[],{"trials":766,"activeCount":78},[767],{"nctId":768,"briefTitle":769,"status":86,"phases":770,"primaryCompletion":771,"completion":772,"start":773,"enrollment":774,"conditions":775,"interventions":777},"NCT03857256","Compare the Efficacy and Safety of Beta-Glucan as Add-On to Statin in Subjects With Hyperlipidemia.",[67],"2021-08-31","2021-12-31","2019-05-31",263,[776],"Hyperlipidemias",[759],{"trials":779,"activeCount":78},[],{"trials":781,"activeCount":78},[],{"trials":783,"activeCount":78},[],{"intervention":785,"totalTrials":152,"cells":786},"Hesperidin",{"EARLY_PHASE1":787,"PHASE1":789,"PHASE2":791,"PHASE3":820,"PHASE4":822,"NA":824},{"trials":788,"activeCount":78},[],{"trials":790,"activeCount":78},[],{"trials":792,"activeCount":78},[793],{"nctId":794,"briefTitle":795,"status":86,"phases":796,"primaryCompletion":797,"completion":798,"start":799,"enrollment":800,"conditions":801,"interventions":819},"NCT04715932","Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN)",[67],"2021-05-25","2021-06-07","2021-02-18",216,[802,803,804,805,806,807,808,809,810,811,812,813,814,815,816,817,818],"Covid19","Anosmia","Fever","Cough","Shortness of Breath","Sore Throat","Nausea","Vomiting","Headache","Muscle Weakness","Pain, Muscle","Pain, Chest","Pain, Joint","Pain, Abdominal","Pain","Irritable Mood","Confusion",[785],{"trials":821,"activeCount":78},[],{"trials":823,"activeCount":78},[],{"trials":825,"activeCount":78},[],{"intervention":827,"totalTrials":152,"cells":828},"Itraconazole 400 mg\u002Fday and terbinafine 500 mg\u002Fday administered orally.",{"EARLY_PHASE1":829,"PHASE1":831,"PHASE2":833,"PHASE3":846,"PHASE4":848,"NA":850},{"trials":830,"activeCount":78},[],{"trials":832,"activeCount":78},[],{"trials":834,"activeCount":78},[835],{"nctId":836,"briefTitle":837,"status":98,"phases":838,"primaryCompletion":839,"completion":839,"start":840,"enrollment":841,"conditions":842,"interventions":845},"NCT05049525","Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease",[67],"2024-02-28","2022-02-22",16,[843,844],"Crohn's Disease","Inflammatory Bowel Diseases",[827],{"trials":847,"activeCount":78},[],{"trials":849,"activeCount":78},[],{"trials":851,"activeCount":78},[],{"intervention":853,"totalTrials":152,"cells":854},"Medical Therapy",{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":861,"PHASE4":863,"NA":865},{"trials":856,"activeCount":78},[],{"trials":858,"activeCount":78},[],{"trials":860,"activeCount":78},[],{"trials":862,"activeCount":78},[],{"trials":864,"activeCount":78},[],{"trials":866,"activeCount":78},[867],{"nctId":868,"briefTitle":869,"status":98,"phases":870,"primaryCompletion":871,"completion":872,"start":873,"enrollment":18,"conditions":874,"interventions":876},"NCT03891823","Transcatheter Mitral Valve Repair for the Treatment of Mitral Valve Regurgitation In Heart Failure (The EVOLVE-MR Trial)",[70],"2024-03-28","2024-05-15","2019-03-08",[875],"Ventricular Remodeling, Left",[853],{"intervention":878,"totalTrials":152,"cells":879},"Edoxaban Pill",{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":886,"PHASE4":888,"NA":890},{"trials":881,"activeCount":78},[],{"trials":883,"activeCount":78},[],{"trials":885,"activeCount":78},[],{"trials":887,"activeCount":78},[],{"trials":889,"activeCount":78},[],{"trials":891,"activeCount":78},[892],{"nctId":893,"briefTitle":894,"status":86,"phases":895,"primaryCompletion":896,"completion":897,"start":898,"enrollment":899,"conditions":900,"interventions":903},"NCT03488420","Canadian EdoxAban(Lixiana®) Registry in Patients With ATrial Fibrillation\u002FFlutter With Confirmed ValvUlar HeaRt DiseasE",[],"2025-03-21","2025-04-03","2019-04-30",136,[901,902],"Atrial Fibrillation and Flutter","Valvular Heart Disease",[878],{"intervention":905,"totalTrials":152,"cells":906},"Standard administration of protamine",{"EARLY_PHASE1":907,"PHASE1":909,"PHASE2":911,"PHASE3":913,"PHASE4":915,"NA":917},{"trials":908,"activeCount":78},[],{"trials":910,"activeCount":78},[],{"trials":912,"activeCount":78},[],{"trials":914,"activeCount":78},[],{"trials":916,"activeCount":78},[],{"trials":918,"activeCount":78},[919],{"nctId":920,"briefTitle":921,"status":86,"phases":922,"primaryCompletion":923,"completion":923,"start":924,"enrollment":925,"conditions":926,"interventions":928},"NCT00684450","Cardiac Surgery: In Vivo Titration of Protamine",[70],"2011-06","2008-06",138,[927],"Bleeding",[905],{"intervention":930,"totalTrials":152,"cells":931},"Sacubitril \u002F Valsartan Oral",{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":938,"PHASE4":940,"NA":942},{"trials":933,"activeCount":78},[],{"trials":935,"activeCount":78},[],{"trials":937,"activeCount":78},[],{"trials":939,"activeCount":78},[],{"trials":941,"activeCount":78},[],{"trials":943,"activeCount":78},[944],{"nctId":945,"briefTitle":946,"status":98,"phases":947,"primaryCompletion":948,"completion":949,"start":950,"enrollment":951,"conditions":952,"interventions":954},"NCT05117736","ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure",[70],"2023-03-01","2023-03-12","2022-03-15",15,[953,15],"Systemic Right Ventricle",[930],{"intervention":956,"totalTrials":152,"cells":957},"Optimal Medical Therapy",{"EARLY_PHASE1":958,"PHASE1":960,"PHASE2":962,"PHASE3":964,"PHASE4":966,"NA":968},{"trials":959,"activeCount":78},[],{"trials":961,"activeCount":78},[],{"trials":963,"activeCount":78},[],{"trials":965,"activeCount":78},[],{"trials":967,"activeCount":78},[],{"trials":969,"activeCount":78},[970],{"nctId":971,"briefTitle":972,"status":626,"phases":973,"primaryCompletion":974,"completion":975,"start":976,"enrollment":78,"conditions":977,"interventions":979},"NCT02985268","Evaluation of Outcomes of CRT and MitraClip for Treatment of Low Ejection Fraction and Functional Mitral Regurgitation in HF",[70],"2019-12","2020-02","2016-12",[978,15],"Functional Mitral Regurgitation",[956]]